DayTwo BOYCOTT

DayTwo offers a sustainable path to remission for metabolic disease (diabetes, prediabetes, clinical obesity, non-alcoholic fatty liver disease) that uses gut microbiome sequencing, artificial intelligence, and virtual care. After 10 years of scientific research, and the development of an AI-based algorithm that predicts blood sugar response to food, DayTwo’s virtual care solution reduces or eliminates medications by improving Time in Range and lowering A1C.